Table 2

Univariate and multivariate analyses of RFS and OS with TLS and clinicopathological characteristics in the Fudan cohort and external validation set

Fudan cohort (n=182)External validation set (n=125)
Univariate analysesMultivariate analysesUnivariate analysesMultivariate analyses
HR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P value
RFS
 AJCC8th TNM stage
 (III/II/I)
2.9 (1.98–4.28)<0.0012.8 (1.79–4.27)<0.0016.1 (3.37–10.95)<0.0014.0 (2.05–7.73)<0.001
 WHO classification
 (G3/G2/G1)
4.3 (2.45–7.71)<0.0012.9 (1.57–5.22)0.0019.8 (4.22–22.97)<0.0014.3 (1.70–11.01)0.002
 Vascular invasion
 (positive vs negative)
1.9 (1.05–3.41)0.0332.2 (1.09–4.49)0.029
 Presence of TLS
 (yes vs no)
0.3 (0.12–0.54)<0.0010.3 (0.14–0.69)0.0040.2 (0.06–0.45)<0.0010.2 (0.07–0.62)0.005
OS
 AJCC8th TNM stage
 (III/II/I)
2.6 (1.42–4.69)0.0022.2 (1.14–4.20)0.0193.5 (1.87–6.48)<0.0012.2 (1.11–4.38)0.024
 WHO classification
 (G3/G2/G1)
4.5 (2.12–9.38)<0.0013.0 (1.33–6.75)0.00810.6 (3.49–31.87)<0.0015.2 (1.63–16.85)0.005
 Presence of TLS
 (yes vs no)
0.3 (0.11–0.64)0.0030.3 (0.12–0.74)0.0090.2 (0.06–0.44)<0.0010.3 (0.09–0.82)0.020
  • AJCC8th, 8th edition American Joint Committee on Cancer; G3/G2/G1, grade 3/grade 2/grade 1; OS, overall survival; RFS, recurrence-free survival; TLS, tertiary lymphoid structures; TNM, tumor-node-metastasis.